Second Quarter and Fiscal 2024 Outlook
While economic uncertainty persists in parts of our business, we maintain a generally optimistic outlook. For full year fiscal 2024, we are increasing
Financial Guidance
Bristol Myers Squibb is adjusting its 2022 GAAP line-item guidance as follows:
Adjusting GAAP EPS guidance primarily due to the acquisition of Turning Point and reaffirming